Compare Neurocrine Biosciences Inc (NBIX) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Sony Group Corp — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Sony Group Corp trades at $24.12 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 9.5× Neurocrine Biosciences Inc's market cap, and Sony Group Corp pays a 0.66% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Sony Group Corp for 96 Days on average.
| NBIX | SONY | |
|---|---|---|
Market Cap | $14.36B | $136.87B |
Volume | 1,237,180 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $185.50 | $30.26 |
52-Week Low | $123.10 | $19.32 |
Typical Hold Time | 23 Days | 96 Days |
Enterprise Value | $14.37B | $134.77B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Sony trades at $23.95, up 1.83% with bullish technical signals from moving averages. The company shows strong operating cash flow of $2.32T in 2025 and has beaten earnings expectations in two of the last three quarters. Analyst consensus is strongly positive with 11 buy ratings and no sell recommendations. Recent news highlights Sony's content strength and AI-related legal actions against Anthropic.
While Sony demonstrates financial strength with improving cash flow and revenue growth, investors face risks from projected 2026 net losses and competitive pressures. The stock's current valuation appears reasonable with P/E of 20.34, but margin compression and content industry disruption require careful monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
